Nic PreyatAssociate Director, Gene Therapy CMC Development at UCB PharmaSpeaker
Profile
Nic Preyat holds a PhD in Immunobiology. His academic research focused on understanding cell and molecular mechanisms controlling the immune response, and cell death pathways. During his post-doctoral studies, Nic Preyat investigated the possible implementation of new therapeutic strategies to fight cancer. He also developed tools to characterize biomarkers for inflammatory diseases. Nic had several scientific and leadership positions within two global CDMOs, Masthercell and Catalent, developing and manufacturing cell and gene therapy products. Nic Preyat had contributed to the development of various products ranging from viral vectors to CART from early development to transition for commercial manufacturing. At UCB Nic Preyat is now leading a team responsible for the development and manufacturing of rAAV with the ultimate goal to treat patients with neurodegenerative disorders. Through the various positions he assumed, Nic Preyat has acquired a strong expertise in cell culture, CMC development, technology transfer, good manufacturing practices and project management.
Agenda Sessions
Gene Therapy Development: from process design to process intensification at warp speed
, 11:00View Session